Autres langues OLIPASS Corporation

Actions

A244460

KR7244460002

Recherche biotechnologique et médicale

Cours en clôture Korea S.E. 07/04/2025			Varia. 5j.	Varia. 1 janv.
1 651,00 ^KRW	-13,92%		-.--%	-

13/11/23	OliPass Corporation dévoile les résultats cliniques douloureux mais hilarants d'un essai de phase 2a chez des patients souffrant d'arthrose avec l'inhibiteur sélectif de Nav1.7 OLP-1002	CI
20/03/23	OLIPASS Corporation annonce ses résultats pour l'exercice clos le 31 décembre 2022	CI

Autres langues

29/12	OLIPASS Corporation announced that it has received KRW 600 million in funding
18/12	OLIPASS Corporation announced that it expects to receive KRW 600 million in funding
08/12	OLIPASS Corporation announced that it has received KRW 739 million in funding from Genocure Co., Ltd. and other investors.
28/11	OLIPASS Corporation announced that it expects to receive KRW 739 million in funding from Genocure Co., Ltd. and other investors
21/11	OLIPASS Corporation announced that it has received KRW 600 million in funding from Genocure Co., Ltd.
13/11	OLIPASS Corporation announced that it expects to receive KRW 600 million in funding from Genocure Co., Ltd.
25/06/25	OLIPASS Corporation cancelled the transaction announced on December 6, 2024
01/04/25	OLIPASS Corporation announced that it has received KRW 2 billion in funding
31/03/25	OLIPASS Corporation announced that it expects to receive KRW 2 billion in funding
27/12/24	OLIPASS Corporation announced that it has received KRW 3.0000031 billion in funding from Invest Partners No. 1
06/12/24	OLIPASS Corporation announced that it expects to receive KRW 19.99998708 billion in funding
13/11/24	OLIPASS Corporation announced that it expects to receive KRW 3.0000031 billion in funding from Invest Partners No. 1
28/08/24	OLIPASS Corporation announced that it has received KRW 5.500000471 billion in funding from Infraflex Ltd, Thecity Co., Ltd., Optimum New Growth Fund
10/06/24	OLIPASS Corporation announced that it has received KRW 3.5 billion in funding
29/05/24	OLIPASS Corporation announced that it has received KRW 2.501 billion in funding
18/03/24	OLIPASS Corporation amended terms of the transaction
06/03/24	OLIPASS Corporation announced that it expects to receive KRW 5 billion in funding
18/12/23	OLIPASS Corporation announced that it expects to receive KRW 12.50000032 billion in funding
13/11/23	OliPass Corporation Discloses Painful But Hilarious Clinical Findings from a Phase 2a Trial in OA Patients with Nav1.7 Selective Inhibitor OLP-1002
18/09/23	OLIPASS Corporation announced that it has received KRW 4.99998978 billion in funding
04/09/23	OLIPASS Corporation announced that it expects to receive KRW 4.999998885 billion in funding
04/09/23	OLIPASS Corporation announced that it expects to receive KRW 4.99998978 billion in funding
24/08/23	OLIPASS Corporation(KOSDAQ:A244460) dropped from S&P Global BMI Index
20/03/23	OLIPASS Corporation Reports Earnings Results for the Full Year Ended December 31, 2022
16/03/23	OliPass Corporation Announces Nav1.7 Selective Inhibitor OLP-1002 Shows Strong Efficacy and Long Therapeutic Duration According to Interim Findings from Phase 2A Study in OA Patients